Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
 
  • Details

Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data

Journal
Journal of Microbiology, Immunology and Infection
Journal Volume
53
Journal Issue
4
Pages
569-577
Date Issued
2020
Author(s)
CHUN-MING HONG  
CHEN-HUA LIU  
TUNG-HUNG SU  
HUNG-CHIH YANG  
PEI-JER CHEN  
Chen Y.-W
JIA-HORNG KAO  
CHUN-JEN LIU  
DOI
10.1016/j.jmii.2018.09.005
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054592874&doi=10.1016%2fj.jmii.2018.09.005&partnerID=40&md5=b35409a7127ee3b499f970ca6ac5bbd3
https://scholars.lib.ntu.edu.tw/handle/123456789/551047
Abstract
Background/purpose: Treatment of chronic hepatitis C (CHC) has entered a new era since the introduction of direct-acting antiviral agents (DAAs). Numerous clinical trials have shown that treatment response as well as tolerability of DAAs are superior to those of conventional therapy with pegylated interferon and ribavirin. However, the results of clinical trials may not be directly applied to real-world practice. Therefore our study tried to investigate the effectiveness of various DAA regimens in Taiwanese patients with chronic hepatitis C. Methods: We performed a retrospective study on 400 CHC patients. The primary endpoint was undetectable HCV RNA (an HCV RNA level of <25 IU/mL) at 12 weeks posttreatment (SVR12). The results were stratified by different DAAs and HCV genotypes. Results: Genotype 1b was the major genotype (297, 74.3%), followed by genotype 2 (65, 16.3%). The patients were treated according to HCV genotype, clinical practice and reimbursement guidelines. The SVR12 rates of 57 patients treated with sofosbuvir and ribavirin, 107 treated with ledipasvir/sofosbuvir with or without ribavirin, 60 treated with daclatasvir/asunaprevir with or without ribavirin, 129 treated with ombitasvir/paritaprevir/ritonavir/dasabuvir with or without ribavirin, 12 treated with sofosbuvir/daclatasvir with or without ribavirin, and 35 treated with elbasvir/grazoprevir were 98.2%, 97.2%, 85.0%, 97.7%, 100.0%, and 100.0%, respectively. Conclusions: The overall SVR12 rates in our study were comparable with those in previous pivotal trials. DAAs are generally safe. The interaction of HBV and HCV during DAA therapy and the observation of de novo HCC development and HCC recurrence during or after DAAs warrants additional studies. ? 2018
SDGs

[SDGs]SDG3

Other Subjects
alanine aminotransferase; aspartate aminotransferase; asunaprevir; daclatasvir; dasabuvir plus ombitasvir plus paritaprevir plus ritonavir; elbasvir plus grazoprevir; ledipasvir plus sofosbuvir; ribavirin; sofosbuvir; antivirus agent; virus RNA; adult; aged; antiviral therapy; Article; chronic hepatitis C; combination drug therapy; controlled study; dizziness; drug safety; drug tolerability; female; genotype; Hepatitis C virus subtype 1b; human; liver transplantation; major clinical study; male; practice guideline; pruritus; reimbursement; side effect; Taiwan; virus load; blood; chronic hepatitis C; classification; drug effect; genetics; Hepacivirus; middle aged; retrospective study; very elderly; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; RNA, Viral; Taiwan
Publisher
Elsevier Ltd
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science